07Mar 2024
Roche and Alnylam's Zilebesiran Shows Promise in Phase II Study for Hypertension Treatment

Roche and Alnylam's Zilebesiran Shows Promise in Phase II Study for Hypertension Treatment

Roche and Alnylam reported positive results from the Phase II KARDIA-2 study of zilebesiran, an RNAi therapeutic for hypertension. The study enrolled 672 adults with mild-to-moderate hypertension, utilising zilebesiran's RNAi mechanism to target angiotensinogen for durable blood pressure reduction. Zilebesiran, in combination with standard hypertension medication, demonstrated a significant reduction in systolic blood pressure at month three, meeting the primary endpoint. With encouraging safety and tolerability, zilebesiran offers the potential for sustained blood pressure control with twice-yearly dosing, aiming to reduce the risk of cardiovascular events associated with hypertension.

  • #family health

Like

Save

Share